06:46 EDT G1 Therapeutics reaffirms FY23 COSELA net revenue view $50M-$60M
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GTHX:
- G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
- G1 Therapeutics to Participate in Two August Investor Conferences
- G1 Therapeutics announces publication on real world impact of trilaciclib
- New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- GTHX Upcoming Earnings Report: What to Expect?